ADAMAS PHARMACEUTICALS,INC. (NASDAQ:ADMS) Files An 8-K Entry into a Material Definitive Agreement

ADAMAS PHARMACEUTICALS,INC. (NASDAQ:ADMS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01Entry into a Material Definitive Agreement.

Story continues below

On January 16, 2018, Adamas Pharmaceuticals,Inc., (the “Company”), amended its lease agreement with KBIII Towers at Emeryville, LLC (the “Towers”) to extend its lease until April 30, 2025, and relocate the Company within its current building from the seventh to the tenth and eleventh floors, containing approximately 37,626 rentable square feet (the “Amendment”). The relocation of the Company is expected to occur no later than the second quarter of 2018. Upon relocation, the Company shall pay a base rent of $159,911 for the first twelve months, with the monthly rent increasing approximately $5,000 in each subsequent year until the expiration of the lease.

The above description of the Amendment is a summary of the material terms of the Amendment, does not purport to be complete and is qualified in its entirety by reference to the Amendment which will be filed as an exhibit to the Adamas Pharmaceuticals,Inc. Annual Report on Form10-K for the year ending December 31, 2017.

Item 1.01Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information in Item 1.01 above is incorporated by reference into this Item 1.01.


About ADAMAS PHARMACEUTICALS,INC. (NASDAQ:ADMS)

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

An ad to help with our costs